My­lan, Am­gen score unan­i­mous Ad­Comm back­ing for Roche copy­cats; Alder rais­es $161M

My­lan and Am­gen breezed through their ad­vi­so­ry com­mit­tee re­views on Thurs­day with­out any un­ex­pect­ed kick­backs for their two new knock­offs of a pair of Roche megablock­busters. Both won nods in unan­i­mous votes, which is what you’d ex­pect for drugs giv­en a clean as­sess­ment by FDA in­sid­ers. My­lan was up with MYL-1401O, a biosim­i­lar of Her­ceptin. Am­gen, mean­while, won ap­plause for its copy­cat of Avastin.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.